MedTrace Logo

Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI

NCT04856059 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-04-16

No results posted yet for this study

Summary

This study will evaluate whether cardiac MRI T1 and T2 mapping improves our ability to detect early abnormalities in the heart in patients with Fabry disease and identify patients at increase risk of adverse events.

Conditions

Interventions

DIAGNOSTIC_TEST

Cardiac MRI, ECG/Holter and Blood Biomarkers

Cardiac MRI including T1/T2 mapping, ECG and blood biomarker evaluation will be performed at baseline and follow-up

Sponsors & Collaborators

  • Vancouver General Hospital

    collaborator OTHER

  • The Cleveland Clinic

    collaborator OTHER

  • Icahn School of Medicine at Mount Sinai

    collaborator OTHER

  • IRCCS Policlinico S. Donato

    collaborator OTHER

  • Alberta Health services

    collaborator OTHER

  • Libin Cardiovascular Institute of Alberta

    collaborator OTHER

  • Vancouver Coastal Health

    collaborator OTHER_GOV

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Kate Hanneman · University Health Network, Toronto

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2029-03-31
Completion
2029-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04856059 on ClinicalTrials.gov